Drugs / Two-cycle induction chemotherapy + immunotherapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06811844 | Feb 2025 → Dec 2027 expected | nasopharyngeal carcinoma | The First Affiliated Hospital of Xiamen University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Two-cycle induction chemotherapy + immunotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06811844 ↗ |
| Route | Oral | “oral S1 twice daily from days 1 to 14” NCT06811844 ↗ |